Roche Holding (OTCQX:RHHBY) Q2 results (CHF): Revenues: 30,469M (+8.4%); Pharmaceuticals: 24,194M (+10.7%); Diagnostics: 6,275M (+0.2%).
Top-selling Pharmaceuticals: Avastin: 3,659M (+7%); MabThera/Rituxan: 3,339M (-4%); Herceptin: 3,264M (-9%); Perjeta: 1,755M (+34%); Ocrevus: 1,735M (+63%); Actemra/RoActemra: 1,135M (+8%); Xolair: 972M (+1%); Lucentis: 928M (+10%); Tecentriq: 782M (+141%); Activase/TNKase: 686M (+2%).
Net Income: 8,904M (+18.5%); Non-GAAP EPS: 11.12 (13.0%).
2019 Guidance: Sales: mid- to high-single digit growth, at constant exchange rates.
https://seekingalpha.com/news/3481514-roche-q2-top-line-8-percent
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.